Deciphera Pharmaceuticals Announces Second Quarter 2023 Fina

– Second Quarter 2023 Total Revenue of $38.3 Million; Net Product Revenue for QINLOCK® (ripretinib) Increased 18% to $37.3 Million Compared to Second Quarter 2022 –– Top-line Results for MOTION Pivotal Phase 3 Study of Vimseltinib Expected in Fourth Quarter 2023 –– INSIGHT Pivotal Phase 3 Study of QINLOCK in Second-...

Related Keywords

Italy , Switzerland , Israel , Australia , New Zealand , Canada , China , United States , Taiwan , Waltham , Leicestershire , United Kingdom , Macau , Hong Kong , Singapore , Canadian , American , Daniell Flynn , Dan Flynn , Jamesa Bristol , Maghan Meyers , Steve Hoerter , Dashyant Dhanak , David Rosen , Pfizer Inc , Deciphera Pharmaceuticals Inc , Research Engine , Exchange Commission , Pfizer , Deciphera Pharmaceuticals , American Association For Cancer , Linkedin , American Society Of Clinical Oncology , Nasdaq , Incyte Corporation , Company Founder , Chairperson Or Co , Canadian Pharmaceutical Alliance , Zai Lab , Drug Administration , European Union , Second Quarter , Net Product Revenue , Top Line Results , Vimseltinib Expected , Fourth Quarter , First Sites Open , Escalation Cohorts , Cetuximab Initiated , First Site Open , Combination Dose Escalation Cohorts , Inhibitors Ongoing , Chief Executive Officer , Investigational New Drug , Dash Dhanak , Chief Scientific Officer , Clinical Oncology , Annual Meeting , Series Session , American Association , Executive Vice President , Senior Advisor , Ron Squarer , Private Securities Litigation Reform Act , Quarterly Report , Months Ended June ,